Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant enterococcus faecium from renal transplant patients with infected urinary stents

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1518-1520

  Descourouez, Jillian L ^b   Jorgenson, Margaret R ^b   Wergin, Justine E ^a   Rose, Warren E ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; DAPTOMYCIN; FOSFOMYCIN; LINEZOLID; MINOCYCLINE; NITROFURANTOIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; CLINICAL ARTICLE; COLONY FORMING UNIT; DRUG EFFICACY; ENTEROCOCCUS FAECIUM; HUMAN; IC 50; IN VITRO STUDY; KIDNEY TRANSPLANTATION; LIMIT OF DETECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; UROLOGIC STENT; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; AMOXICILLIN; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG SYNERGISM; ENTEROCOCCUS FAECIUM; FOSFOMYCIN; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY TRANSPLANTATION; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STENTS; URINARY TRACT; URINARY TRACT INFECTIONS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84874096986     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02099-12     Document Type: Article

References (14)

1. Sood S, Malhotra M, Das BK, Kapil A. 2008. Enterococcal infections & antimicrobial resistance. Indian J. Med. Res. 128:111-121.
2. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. 2009.Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int. J. Antimicrob. Agents. 34:506 -515.
3. Neuner EA, Sekeres J, Hall GS, van Duin D. 2012. Experience with fosfomycin for treatment of urinary tract infections due to multidrugresistant organisms. Antimicrob. Agents Chemother. 56:5744 -5748.
4. Descourouez JL, Jorgenson M, Rose W. 2011. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr E-1322.
5. Clinical and Laboratory Standards Institute. 2011. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 11th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Rose WE, Poppens PT. 2009. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J. Antimicrob. Chemother. 63:485- 488.
7. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771- 1776.
8. Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ. 2008. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J. Antimicrob. Chemother. 61:365-370.
9. Heintz BH, Halilovic J, Christensen CL. 2010. Vancomycin-resistant enterococcal urinary tract infections. Pharmacotherapy 30:1136 -1149.
10. Chen LY, Huang CH, Kuo SC, Hsiao CY, Lin ML, Wang FD, Fung CP. 2011. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report. BMC Infect. Dis. 11:152.
11. Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F. 2001. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J. Antimicrob. Chemother. 48:209 -217.
12. Utsui Y, Ohya S, Magaribuchi T, Tajima M, Yokota T. 1986. Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 30:917-922.
13. Zhanel GG, Laing NM, Nichol KA, Palatnick LP, Noreddin A, Hisanaga T, Johnson JL, Hoban DJ, NAVRESS Group. 2003. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). J. Antimicrob. Chemother. 52:382-388.
14. de Souza RM, Olsburgh J. 2008. Urinary tract infection in the renal transplant patient. Nat. Clin. Pract. Nephrol. 4:252-264.